Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis

This study has been completed.
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Cephalon ) Identifier:
First received: December 21, 2007
Last updated: September 22, 2015
Last verified: September 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2010
  Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: August 22, 2013